{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:45:24Z","timestamp":1785545124844,"version":"3.56.0"},"reference-count":35,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Mhealth Uhealth"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The Chinese National Guidelines on Diagnosis and Treatment of Gonorrhea (2020) recommend ceftriaxone 1 g intramuscularly as a single dose for the treatment of uncomplicated gonococcal infections. However, nonadherence to the guidelines remains common among physicians in China, partly due to their poor awareness of the recommendations.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This trial aimed to (1) assess the effectiveness of an app-based training tool in improving adherence to guideline-recommended treatment regimens and (2) identify reasons for nonadherence among physicians who used the training tool.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using a cluster randomized controlled trial design, we randomly allocated 72 hospitals (clusters) from 4 provinces to the intervention (n=36, 50%) or control (n=36, 50%) arms in a 1:1 ratio. In the intervention arm, physicians received free app-based training via smartphones for 6 months, while the control arm continued routine training. The primary outcome was the proportion of prescriptions adherent to the regimens for treatment of uncomplicated gonorrhea recommended by the national guidelines. We analyzed cluster-level summary outcomes at endline using methods appropriate for stratified cluster randomized controlled trials with relatively few clusters per group, accounting for between-cluster variation. A postintervention survey was administered to all intervention-arm physicians to evaluate their experience with the app-based training module. Additionally, face-to-face interviews were conducted with 32 purposely selected nonadherent physicians from the intervention arm to explore reasons for nonadherence.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 715 physicians (n=343, 48% in the control arm and n=372, 52% in the intervention arm) participated in the study. Over the 6-month intervention period, the adherence to 1 g ceftriaxone for the treatment of uncomplicated gonorrhea increased from 53.6% to 54.8% in the intervention arm, whereas the rate decreased from 43.9% to 42.5% in the control arm. The mean difference (5.5%, 95% CI \u22127% to 18%;\n P<\/jats:italic>\n =.37) in changes in the adherence rate between intervention and control arms was not statistically significant (risk ratio 1.12, 95% CI 0.93\u20101.35;\n P<\/jats:italic>\n =.23). Among the 32 (19%) nonadherent physicians from the intervention arm, the primary reason for nonadherence was their concern regarding the sufficiency of the currently recommended dosage of generic ceftriaxone for treating gonorrhea.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In our study, the implementation of an app-based training tool did not improve adherence to treatment recommendations. Concern regarding the efficacy of generic ceftriaxone may be one of the intrinsic factors associated with nonadherence.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/63736","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:15:12Z","timestamp":1769724912000},"page":"e63736-e63736","source":"Crossref","is-referenced-by-count":0,"title":["App-Based Training Module on Guiding Physicians\u2019 Prescription for Antibiotic Treatment of Gonorrhea: Cluster Randomized Controlled Trial"],"prefix":"10.2196","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-8816","authenticated-orcid":false,"given":"Ting-Ting","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3289-258X","authenticated-orcid":false,"given":"Xiao-Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-3744","authenticated-orcid":false,"given":"Pei-Zhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-0637","authenticated-orcid":false,"given":"Li-Juan","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5847-7020","authenticated-orcid":false,"given":"Hui-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3783-2359","authenticated-orcid":false,"given":"Yun-Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2747-0560","authenticated-orcid":false,"given":"Man-Hong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8000-9969","authenticated-orcid":false,"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5463-4963","authenticated-orcid":false,"given":"Yun-Liang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3455-3620","authenticated-orcid":false,"given":"Yu-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-4361","authenticated-orcid":false,"given":"Yan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1700-2750","authenticated-orcid":false,"given":"Yue-Ping","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3927-2065","authenticated-orcid":false,"given":"Xiang-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"R1","unstructured":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. World Health Organization. 2021. URL: https:\/\/www.who.int\/publications\/i\/item\/9789240027077\/ [Accessed 18-03-2024]"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"R3","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/cid\/ciy271","article-title":"A brief history of evolving diagnostics and therapy for gonorrhea: lessons learned","volume":"67","author":"Hook","journal-title":"Clin Infect Dis"},{"issue":"11","key":"R4","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41564-019-0501-y","article-title":"The impact of antimicrobials on gonococcal evolution","volume":"4","author":"S\u00e1nchez-Bus\u00f3","journal-title":"Nat Microbiol"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420949126","article-title":"2020 European guideline for the diagnosis and treatment of gonorrhoea in adults","author":"Unemo","journal-title":"Int J STD AIDS"},{"issue":"4","key":"R6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"R7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3201\/eid1701.100397","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae, Japan","volume":"17","author":"Ohnishi","journal-title":"Emerg Infect Dis"},{"issue":"26","key":"R8","first-page":"873","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"R9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.05760-11","article-title":"High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure","volume":"56","author":"Unemo","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"R10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.eimc.2011.11.010","article-title":"First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia, Spain, May 2011","volume":"30","author":"Carnicer-Pont","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"27","key":"R11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018","volume":"23","author":"Eyre","journal-title":"Euro Surveill"},{"issue":"8","key":"R12","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.8.1900118","article-title":"Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant cases, United Kingdom and Australia, February to April 2018","volume":"24","author":"Jennison","journal-title":"Euro Surveill"},{"issue":"2","key":"R13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002499","article-title":"Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: a retrospective study of national surveillance data from 2013 to 2016","volume":"15","author":"Yin","journal-title":"PLoS Med"},{"issue":"3","key":"R14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/JD9.0000000000000072","article-title":"National guidelines on diagnosis and treatment of gonorrhea in China (2020)","volume":"3","author":"Wang","journal-title":"Int J Dermatol Venereol"},{"issue":"9","key":"R15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/OLQ.0000000000000819","article-title":"Nonadherence to national guidelines for antibiotic treatment of uncomplicated gonorrhea in China: results from a nationwide survey","volume":"45","author":"Han","journal-title":"Sex Transm Dis"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/cid\/ciz170","article-title":"Widespread use of high-dose ceftriaxone therapy for uncomplicated gonorrhea without reported ceftriaxone treatment failure: results from 5 years of multicenter surveillance data in China","volume":"70","author":"Han","journal-title":"Clin Infect Dis"},{"key":"R17","unstructured":"Chinese Clinical Trial Registry [Website in Chinese]. URL: https:\/\/www.chictr.org.cn\/ [Accessed 22-02-2026]"},{"key":"R18","unstructured":"Xieshou app [Website in Chinese]. URL: https:\/\/www.xieshoue.org [Accessed 23-02-2026]"},{"issue":"7","key":"R19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037549","article-title":"Novel education-based intervention to reduce inappropriate antibiotic prescribing for treatment of gonorrhoea in China: protocol for a cluster randomised controlled trial","volume":"10","author":"Jiang","journal-title":"BMJ Open"},{"issue":"3","key":"R20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11096-012-9637-z","article-title":"Outpatient parenteral antimicrobial therapy with ceftriaxone, a review","volume":"34","author":"Duncan","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"R21","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jval.2012.04.004","article-title":"Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?","volume":"15","author":"Cameron","journal-title":"Value Health"},{"issue":"2","key":"R22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/jebm.12030","article-title":"International experiences of promoting generics use and its implications to China","volume":"6","author":"Sun","journal-title":"J Evid Based Med"},{"issue":"5","key":"R23","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1208\/s12249-014-0133-8","article-title":"Challenges and opportunities to use biowaivers to compare generics in China","volume":"15","author":"Zuo","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"R24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/10543406.2015.1092027","article-title":"Some thoughts on drug interchangeability","volume":"26","author":"Chow","journal-title":"J Biopharm Stat"},{"issue":"4","key":"R25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1248\/cpb.60.429","article-title":"Comparison between original and generic versions of ceftriaxone sodium preparation for injection: compatibility with calcium-containing product","volume":"60","author":"Tange","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"11","key":"R26","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/pds.3232","article-title":"Fatal adverse effects of injected ceftriaxone sodium in China","volume":"21","author":"Yao","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"R27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/1120009X.2022.2153314","article-title":"Quality control and consistency evaluation of ceftriaxone sodium for injection","volume":"35","author":"Chong","journal-title":"J Chemother"},{"issue":"6","key":"R28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1179\/1973947814Y.0000000208","article-title":"Pharmaceutical quality of eight generics of ceftriaxone preparation for injection in eastern Asia","volume":"27","author":"Arnet","journal-title":"J Chemother"},{"issue":"9","key":"R29","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241274513","article-title":"Antibiotic prescription patterns in the emergency department of a tertiary healthcare center in Nepal: a descriptive cross-sectional study","volume":"52","author":"Basnet","journal-title":"J Int Med Res"},{"issue":"3","key":"R30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4103\/picr.PICR_281_20","article-title":"Knowledge, attitude, and practice of generic medicines among physicians at multispecialty hospital: an observational study","volume":"13","author":"Hadia","journal-title":"Perspect Clin Res"},{"issue":"14","key":"R31","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/jama.2017.11152","article-title":"Effects of behavioral interventions on inappropriate antibiotic prescribing in primary care 12 months after stopping interventions","volume":"318","author":"Linder","journal-title":"JAMA"},{"issue":"22","key":"R32","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2013.6287","article-title":"Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial","volume":"309","author":"Gerber","journal-title":"JAMA"},{"issue":"6","key":"R33","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/jama.2016.0275","article-title":"Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial","volume":"315","author":"Meeker","journal-title":"JAMA"},{"issue":"3","key":"R34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/cid\/ciy566","article-title":"A ROADMAP plan to address research needs for gonococcal antimicrobial resistance in China","volume":"68","author":"Chen","journal-title":"Clin Infect Dis"},{"issue":"10","key":"R35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-051277","article-title":"Knowledge, perceptions and practices of pharmacists regarding generic substitution in China: a cross-sectional study","volume":"11","author":"Qu","journal-title":"BMJ Open"}],"container-title":["JMIR mHealth and uHealth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/mhealth.jmir.org\/2026\/1\/e63736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:30:52Z","timestamp":1785537052000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhealth.jmir.org\/2026\/1\/e63736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2196\/63736","relation":{},"ISSN":["2291-5222"],"issn-type":[{"value":"2291-5222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"v14i1e63736"}}